Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844

COLGATE PALMOLIVE CO

CL

Watch

Latest revenue

$5.32B

as of 2026-03-31

Latest net income

$646.0M

as of 2026-03-31

Net margin

12.1%

as of 2026-03-31

Price · 5Y

+4.0% / yr 9.7 pts / yr vs S&P 500 21.7% total
Compare:

Live market

delayed ≤15 min
$90.61
0.19%
Market cap
$72.51B
Enterprise value
$81.34B
P/E (trailing)
34.0×
Forward P/E
P/B
84.70×
Dividend yield
2.3%
52-wk high
$99.33
52-wk low
$74.55
Beta
Shares out
800.2M

5-year trend

What this company does

AI

PART I ITEM 1. BUSINESS General Development of the Business Colgate-Palmolive Company (together with its subsidiaries, “we,” “us,” “our,” the “Company” or “Colgate-Palmolive”) is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. To achieve our business and financial objectives and deliver peer-leading performance and total shareholder return, we are focused on driving organic sales growth; delivering consistent, compounded earnings per share growth; achieving operational efficiencies; and driving growth in free cash flow along with the efficient use of our balance sheet. We do this by leveraging the…

AI summary unavailable — showing raw filing excerpt

Generated from CL's filing dated 2026-02-23

Key risks

AI

ITEM 1A. RISK FACTORS In addition to the risks described elsewhere in this report, set forth below is a summary of the material risks to an investment in our securities. These risks, some of which have occurred and/or are occurring and any of which could occur in the future, are not the only ones we face. Additional risks not presently known to us or that we currently deem immaterial may also have an adverse effect on us. To the extent any of these risks actually occur, our business, results of operations, cash flows and financial condition could be materially and adversely impacted, which might cause the value of our securities to decline. Business and Industry Risks We face risks…

AI summary unavailable — showing raw filing excerpt

Generated from CL's filing dated 2026-02-23

Profitability

Gross margin

60.1%

0.6%

Operating margin

16.2%

23.6%

Net margin

10.5%

27.2%

Return on equity

3948.1%

189.7%

Return on assets

13.1%

27.5%

Leverage

Debt / equity

301.41×

303.6%

Long-term debt / equity

127.24×

270.1%

Debt / assets

99.7%

1.0%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$5.32B+8.4%$646.0M-6.4%12.1%

Q4 2025

2025-12-31

$5.23B+5.8%$-36.0M-104.9%-0.7%

Q3 2025

2025-09-30

$5.13B+1.9%$735.0M-0.3%14.3%

Q2 2025

2025-06-30

$5.11B+1.0%$743.0M+1.6%14.5%

Q1 2025

2025-03-31

$4.91B-3.0%$690.0M+1.0%14.1%

Q4 2024

2024-12-31

$4.95B$738.0M14.9%

Q3 2024

2024-09-30

$5.03B+2.4%$737.0M+4.1%14.6%

Q2 2024

2024-06-30

$5.06B+4.9%$731.0M+45.6%14.5%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844

No data yet for industry average

Your notes

Keep private notes on CL — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$0

Insider selling

$26.1M

Net activity

−$26.1M

Distinct insiders

7

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-05-15

Gregory Malcolm

EVP and Controller

Sale2,300$88.44$203.4K
2026-05-07

Sally Massey

Chief People Officer

Sale8,599$87.41$751.6K
2026-02-12

Panagiotis Tsourapas

COO, Eur., APac, Afr Eur, Skin

Sale15,000$97.81$1.5M
2026-02-11

Panagiotis Tsourapas

COO, Eur., APac, Afr Eur, Skin

Sale35,000$94.61$3.3M
2026-02-10

John Hazlin

Chief Growth Officer

Sale20,989$94.25$2.0M
2026-02-06

Gregory Malcolm

EVP and Controller

Sale12,747$94.91$1.2M

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns CL

Institutional value

$20.08B

Total shares held

240.2M

Distinct holders

747

As of

2026-03-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1VANGUARD CAPITAL MANAGEMENT LLC52.2M$4.45BNew
2VANGUARD PORTFOLIO MANAGEMENT LLC23.8M$2.03BNew
3Bank of New York Mellon Corp12.5M$1.07BNew
4DEUTSCHE BANK AG\11.9M$1.02BNew
5Invesco Ltd.8.3M$710.7MNew
6First Eagle Investment Management, LLC8.1M$691.8MNew
7Legal & General Group Plc5.7M$487.3MNew
8DIAMOND HILL CAPITAL MANAGEMENT INC5.4M$460.8MNew
9DIMENSIONAL FUND ADVISORS LP5.2M$442.3MNew
10STIFEL FINANCIAL CORP5.0M$423.3MNew
11UBS Group AG4.6M$393.3MNew
12VANGUARD FIDUCIARY TRUST CO4.6M$390.8MNew
13WELLS FARGO & COMPANY/MN4.1M$351.6MNew
14Swedbank AB4.0M$337.8MNew
15TD ASSET MANAGEMENT INC3.6M$304.6MNew
16National Pension Service2.3M$198.2MNew
17Swiss National Bank2.2M$191.5MNew
18Nuveen, LLC2.1M$180.9MNew
19BNP PARIBAS FINANCIAL MARKETS2.0M$168.5MNew
20Mitsubishi UFJ Asset Management Co., Ltd.1.9M$164.0MNew

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once CL's latest filing finishes processing.